Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002).Lin Shen, Caroline Germa, Tianshu Liu et al.|Journal of Clinical Oncology|2023Cited by 16
Abstract 2535: Development of Claudin 18.2 IHC 14G11 pharmDx as a clinical trial assay for the clinical development of anti-claudin 18.2 monoclonal antibody osemitamab (TST001) in gastric and gastroesophageal junction adenocarcinomaHayley Alderson, Emin Oroudjev, Katie Lefley et al.|Cancer Research|2024Cited by 2